Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
On Tuesday, Pfizer announced its decision to donate the rights of royalties from sales of the cancer drug Bavencio to the American Association for Cancer Research. This move comes as a response to concerns raised by US antitrust regulators regarding Pfizer's proposed $43 billion acquisition of Seagen.
After receiving all necessary regulatory approvals, the deal is set to close on Thursday, nearly nine months since its initial announcement, as per Reuters.
Reorganization and Leadership Changes
Pfizer plans to establish a separate division dedicated to cancer drugs as part of its efforts to streamline operations. Additionally, the company intends to split its remaining commercial business into two divisions, one focused on the United States and the other on the rest of the world.
Chief Commercial Officer Angela Hwang will step down, allowing Aamir Malik to assume the US unit's commercial chief role. In the international unit, Alexandre de Germay will take on the position of commercial chief.
Sales and Financial Outlook
Bavencio, a vital cancer drug, generated sales amounting to $271 million for Pfizer in 2022. This acquisition of Seagen, with its targeted cancer therapies, comes at a crucial time for Pfizer. Facing the anticipated decline in COVID-related sales and the looming threat of generic competition for its top-selling drugs, Pfizer seeks to bolster its oncology portfolio and maintain its position as a leader in the pharmaceutical industry.
However, the acquisition faced scrutiny from the US Federal Trade Commission (FTC) earlier this year. In July, the FTC requested more information on the deal from both parties involved, seeking to ensure compliance with antitrust laws. Despite this additional hurdle, Pfizer remains committed to moving forward with the acquisition and closing the deal as planned.
Business Times noted that Seagen, based in Washington, is recognized as a pioneer of antibody-drug conjugates. These innovative treatments function like "guided missiles," specifically designed to target and destroy cancer cells while sparing healthy cells. With this cutting-edge technology and expertise, Seagen contributes to advancing more effective and targeted cancer therapies.
Photo: Pfizer Newsroom
